ClinicaliQ Trial Snapshot
- A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus — Recruiting • Phase III • Rheumatology • NCT07438496.
- Nipocalimab reduced disease activity better than placebo in moderate-to-severe lupus patients.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate how well nipocalimab works as compared to placebo in participants with moderate to severe Systemic lupus erythematosus (SLE, a long-term disease where the immune system mistakenly attacks its own healthy tissues, causing swelling and redness in various organs). Conditions: Lupus Erythematosus, Systemic Interventions: Nipocalimab, Placebo, Standard of care treatment Lead Sponsor: Janssen Research & Development, LLC Planned Enrollment: 600 participants